tiprankstipranks
Bicycle Therapeutics (BCYC)
NASDAQ:BCYC
US Market
BCYC
Bicycle Therapeutics
RESEARCH TOOLSreports
Want to see BCYC full AI Analyst Report?

Bicycle Therapeutics (BCYC) Stock News & Sentiment

412 Followers
Analyst Initiates Buy Rating on Nuzetide Developer, Citing Differentiated Efficacy in Urothelial Cancer and Advancing Pancreatic Cancer Program
Premium
Ratings
Analyst Initiates Buy Rating on Nuzetide Developer, Citing Differentiated Efficacy in Urothelial Cancer and Advancing Pancreatic Cancer Program
19d ago
BCYC
Bicycle Therapeutics: Early EphA2-Targeted Data and Multi-Tumor Expansion Potential Support Buy Rating and Upside to Valuation
Premium
Ratings
Bicycle Therapeutics: Early EphA2-Targeted Data and Multi-Tumor Expansion Potential Support Buy Rating and Upside to Valuation
29d ago
BCYC
Bicycle Therapeutics Advances EphA2 Oncology Pipeline With New Data
Premium
Company Announcements
Bicycle Therapeutics Advances EphA2 Oncology Pipeline With New Data
29d ago
8K
BCYC
Bicycle Therapeutics: Portfolio Refocus and Cost Cuts Extend Cash Runway, Strengthening Risk‑Reward and Supporting Buy Rating
Premium
Ratings
Bicycle Therapeutics: Portfolio Refocus and Cost Cuts Extend Cash Runway, Strengthening Risk‑Reward and Supporting Buy Rating
2M ago
BCYC
BCYC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
BCYC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
BCYC
Bicycle Therapeutics Sets 2026 Oncology and Radiopharma Priorities
Premium
Company Announcements
Bicycle Therapeutics Sets 2026 Oncology and Radiopharma Priorities
4M ago
8K
BCYC
Buy Rating for Bicycle Therapeutics: Strong Upside Potential Amid Clinical and Financial Developments
Premium
Ratings
Buy Rating for Bicycle Therapeutics: Strong Upside Potential Amid Clinical and Financial Developments
7M ago
BCYC
More BCYC News >

BCYC News on the Web

Bicycle Therapeutics price target lowered to $12 from $13 at Morgan Stanley
TipRanks News
Bearish
Top Executives Quietly Cash Out at Bicycle Therapeutics
TipRanks News
Bearish
Bicycle Therapeutics: Portfolio Refocus and Cost Cuts Extend Cash Runway, Strengthening Risk‑Reward and Supporting Buy Rating
TipRanks News
Neutral
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)
Zacks
Bullish
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks
Bullish
Bicycle Therapeutics price target lowered to $7 from $11 at RBC Capital
TipRanks News
Bearish
Bicycle Therapeutics price target lowered to $36 from $44 at Oppenheimer
TipRanks News
Bearish
RBC Capital Sticks to Their Hold Rating for Bicycle Therapeutics (BCYC)
TipRanks News
Bearish

News Score - Last 7 Days

Not enough data to generate a sentiment score
BCYC
Sector Average
Media Buzz
This Week1 articles
Weekly Average2.5 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is BCYC’s Media Buzz Sentiment?
1 articles about BCYC were published this week. In an average week, 2.5 articles are published.
    What is BCYC’s weekly average amount of articles?
    In an average week, 2.5 articles about BCYC are published.
      What is BCYC’s News Sentiment?
      Currently, no data Available
      Healthcare Stocks that are Trending in the News
      DOCSDoximity
      AVAHAveanna Healthcare Holdings
      AQSTAquestive Therapeutics
      GOSSGossamer Bio
      HTFLHeartFlow, Inc.
      Showing the stocks with the most bullish news sentiment over the past week